Hong Kong (HSI) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 31 Jul 2026	HK$325.1b	HK$48.6b	HK$1.2b	32.4x	268.7x	6.7x
Sun, 28 Jun 2026	HK$297.4b	HK$48.4b	HK$1.2b	28.4x	255.1x	6.1x
Tue, 26 May 2026	HK$314.2b	HK$48.4b	HK$1.2b	29.3x	267.2x	6.5x
Thu, 23 Apr 2026	HK$350.2b	HK$48.2b	HK$1.1b	31.7x	308.7x	7.3x
Sat, 21 Mar 2026	HK$319.7b	HK$44.7b	HK$1.9b	29.3x	167.9x	7.1x
Mon, 16 Feb 2026	HK$382.4b	HK$43.5b	HK$6.1b	44.8x	62.9x	8.8x
Wed, 14 Jan 2026	HK$365.4b	HK$42.7b	HK$6.4b	49.1x	57.5x	8.6x
Fri, 12 Dec 2025	HK$313.7b	HK$42.2b	HK$6.3b	46.5x	50.1x	7.4x
Sun, 09 Nov 2025	HK$324.1b	HK$41.8b	HK$6.2b	47.4x	52.2x	7.7x
Tue, 07 Oct 2025	HK$396.2b	HK$41.9b	HK$6.2b	52.9x	63.8x	9.5x
Thu, 04 Sep 2025	HK$329.3b	HK$41.9b	HK$6.2b	49.1x	53x	7.9x
Sat, 02 Aug 2025	HK$272.4b	HK$37.1b	HK$2.7b	57.3x	100x	7.3x
Mon, 30 Jun 2025	HK$217.2b	HK$36.8b	HK$2.7b	34.4x	81.1x	5.9x
Wed, 28 May 2025	HK$197.7b	HK$36.1b	HK$2.6b	26.4x	76.1x	5.5x
Fri, 25 Apr 2025	HK$188.8b	HK$35.4b	HK$2.5b	25.9x	74.5x	5.3x
Sun, 23 Mar 2025	HK$217.0b	HK$32.6b	-HK$203,413,550.89	47.8x	-1066.9x	6.6x
Tue, 18 Feb 2025	HK$192.5b	HK$35.9b	-HK$1,058,465,890.85	60x	-181.9x	5.4x
Thu, 16 Jan 2025	HK$149.2b	HK$35.6b	-HK$1,062,134,282.15	57x	-140.4x	4.2x
Sat, 14 Dec 2024	HK$154.0b	HK$35.8b	-HK$1,058,308,029.17	58.8x	-145.5x	4.3x
Mon, 11 Nov 2024	HK$154.2b	HK$36.1b	-HK$1,054,663,570.84	41.4x	-146.3x	4.3x
Wed, 09 Oct 2024	HK$174.7b	HK$36.0b	-HK$653,938,960.90	34.1x	-267.1x	4.9x
Fri, 06 Sep 2024	HK$149.5b	HK$35.9b	-HK$659,801,485.49	23.4x	-226.7x	4.2x
Sun, 04 Aug 2024	HK$97.0b	HK$33.8b	HK$3.1b	19.4x	31x	2.9x
Tue, 02 Jul 2024	HK$89.5b	HK$33.4b	HK$3.1b	19.2x	29.1x	2.7x
Thu, 30 May 2024	HK$91.4b	HK$33.5b	HK$3.1b	28.5x	29.6x	2.7x
Sat, 27 Apr 2024	HK$108.0b	HK$33.6b	HK$3.1b	30.6x	34.9x	3.2x
Mon, 25 Mar 2024	HK$111.8b	HK$33.2b	HK$3.7b	52.8x	30.6x	3.4x
Wed, 21 Feb 2024	HK$126.9b	HK$32.3b	HK$3.0b	51.9x	42.7x	3.9x
Fri, 19 Jan 2024	HK$204.3b	HK$32.3b	HK$3.0b	89.1x	68.6x	6.3x
Sun, 17 Dec 2023	HK$212.6b	HK$32.5b	HK$3.0b	85.2x	70.5x	6.5x
Tue, 14 Nov 2023	HK$263.8b	HK$30.1b	HK$2.7b	46.7x	98.7x	8.8x
Thu, 12 Oct 2023	HK$252.8b	HK$30.1b	HK$2.7b	44.9x	94.7x	8.4x
Sat, 09 Sep 2023	HK$223.8b	HK$30.1b	HK$2.7b	40.1x	84.3x	7.4x
Mon, 07 Aug 2023	HK$243.1b	HK$28.5b	HK$2.7b	23.2x	88.7x	8.5x

Current Industry PE

Investors are optimistic on the Hong Kong Life Sciences Tools and Services industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 281x which is higher than its 3-year average PE of 31.5x.

The 3-year average PS ratio of 5.9x is lower than the industry's current PS ratio of 6.9x.

Past Earnings Growth

The earnings for companies in the Life Sciences Tools and Services industry have declined 24% per year over the last three years.
Meanwhile revenues for these companies have grown 19% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Hong Kong Clinical Research and Equipment compare with similar industries?


HK Market	2.13%
Healthcare	-3.88%
Life Sciences	-4.73%
Clinical Research and Equipment	-4.73%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
1548 Genscript Biotech	HK$18.06	12.2% +HK$4.3b	8.8%	PS5.3x
1873 Viva Biotech Holdings	HK$1.30	5.7% +HK$145.2m	-18.8%	PE10.6x
1521 Frontage Holdings	HK$1.17	2.6% +HK$60.8m	-22.0%	PE44.5x
6118 Austar Lifesciences	HK$0.71	2.9% +HK$10.3m	-51.7%	PE9.3x

Insilico Medicine Launches Drug Discovery and Development Benchmark as A Service

Insilico Medicine announced the launch of the Drug Discovery and Development (DDD) Benchmarks as a Service (BaaS). It is a pioneering standardized evaluation framework anchored in carefully decontaminated real-world data and proprietary validated programs for measuring how frontier AI and foundation models built on other architectures perform on real-world tasks across medicinal chemistry, chemical synthesis, disease biology, clinical development, and longevity research. Insilico's BaaS is available to any organization developing frontier AI for drug discovery or leveraging foundation models in their research. The DDD Benchmark provides an independent, real-world measure of how a model performs. The DDD Benchmark comprises two complementary evaluation suites: Drug Discovery Foundations includes more than 300 evaluations built from proprietary out-of-distribution test sets and rigorously decontaminated public data. It measures a model's core competencies across the discipline — spanning disease biology, molecular property prediction and optimization, retrosynthesis, structure-based design, and clinical development. Drug Candidate Essentials evaluates a model's ability to navigate an end-to-end drug discovery program, from hit identification through preclinical candidate (PCC) nomination. Its reference baselines are anchored in Insilico's own validated programs, testing whether a model can make the sequential, high-stakes decisions that real drug discovery demands. Benchmarking is straightforward: any model served through a standard chat-completions API can be evaluated by contacting Insilico Medicine. Insilico Medicine scores the resulting outputs against expert reference baselines and provides a standardized scorecard comparing performance with leading models. Results are delivered with a verified score report that lets organizations certify performance for internal and partner audiences. Organizations seeking public recognition can also publish their results on the DDD Benchmark public leaderboard, giving the field a transparent, like-for-like view of model capability. The DDD Benchmark is designed to measure whether those capabilities translate into sound, real-world drug discovery decisions rather than strong performance on abstract tasks. The DDD Benchmark builds on Insilico's Pharma.AI platform and the MMAI Gym, the company's post-training environment for scientific AI. Since its founding, Insilico has nominated 31 preclinical candidates, received over 10 investigational new drug (IND) clearances, and compressed the timeline to PCC nomination to roughly 12 to 18 months, compared with the 2.5 to 4-plus years typical of traditional drug discovery. Its lead program, Rentosertib (ISM001-055), is a first-in-class, AI-discovered and AI-designed TNIK inhibitor now in Phase III development for IPF. The DDD Benchmark as a Service is available now.

Hong Kong (HSI) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Insilico Medicine Launches Drug Discovery and Development Benchmark as A Service

Xtalpi Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2026

WuXi Biologics (Cayman) Inc. to Report First Half, 2026 Results on Aug 25, 2026

COO & Executive Director recently sold HK$581k worth of stock

New minor risk - Share price stability

China Health Group Inc., Annual General Meeting, Jul 17, 2026

New minor risk - Share price stability

Zhejiang Taimei Medical Technology Co., Ltd. Announces Board and Committee Appointments, Effective June 23, 2026

Investor sentiment improves as stock rises 17%

Viva Biotech Holdings' (HKG:1873) Profits May Not Reveal Underlying Issues

Full year 2025 earnings released: EPS: CN¥0.066 (vs CN¥0.031 in FY 2024)